Outcome of thyroid function in graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage

L. Chiovato, E. Fiore, P. Vitti, R. Rocchi, T. Rago, D. Dokic, F. Latrofa, C. Mammoli, F. Lippi, C. Ceccarelli, A. Pinchera

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

We investigated the interrelationship and the influence of thyroid- stimulating antibodies (TSAb), TSH-blocking antibodies (TSHBAb), and of radioiodine (131I)-induced thyroid damage in the early (within 1 yr) outcome of thyroid function in hyperthyroid patients with Graves' disease (GD) treated with 131I. TSAb, TSHBAb, and ultrasound thyroid volume (as an index of thyroid damage) were simultaneously measured before and at 1, 3, 6, and 12 months after 131I in 31 GD patients. One year after radioiodine, 9.7% of patients were hyperthyroid (Hyper-group), requiring methimazole; 12.9% were eu-thyroid (Eu-group); and 77.4% were hypothyroid (Hypo-group). Pretreatment thyroid volume in the Eu-group and Hyper-group was significantly greater (P = 0.009) than in the Hypo-group. Pre-131I TSAb levels were higher in the Hyper-group vs. the Hypo-group (P = 0.01) or the Eu-group (P = 0.03). A significant post-131I increase in TSAb levels occurred in 66% of patients developing hypothyroidism but not in those remaining hyperthyroid. After 131I, TSHBAb appeared in 7 patients, in all but one associated with high levels of TSAb. One year after radioiodine: 1) the mean percent reduction in thyroid volume was greater in the Hypo-group (80.7%) or the Eu- group (83.5%) than in the Hyper-group (35.7%) (P = 0.007 and 0.033, respectively); 2) hypothyroid patients had smaller (P = 0.0058) post-131I thyroids than hyperthyroid patients; and 3) TSAb were still elevated in 75% hypothyroid patients, but all of them had a thyroid volume ≤8 mL, indicating major postradioiodine gland damage. In conclusion: 1) the early outcome of thyroid function after 131I for GD is mainly related to pretreatment thyroid volume and to the degree of its reduction after therapy; 2) high TSAb levels before 131I are associated with a relative resistance to therapy; 3) a postradioiodine increase in TSAb levels is related to the development of hypothyroidism; and 4) the concomitant appearance of TSHBAb and disappearance of TSAb are not frequent after 131I and play a role in the development of early postradioiodine hypothyroidism only in a minority of patients.

Original languageEnglish
Pages (from-to)40-46
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume83
Issue number1
DOIs
Publication statusPublished - 1998

Fingerprint

Thyroid-Stimulating Immunoglobulins
Blocking Antibodies
Thyrotropin
Thyroid Gland
Hyperthyroidism
Graves Disease
Hypothyroidism
Methimazole
Ultrasonics

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Outcome of thyroid function in graves' patients treated with radioiodine : Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. / Chiovato, L.; Fiore, E.; Vitti, P.; Rocchi, R.; Rago, T.; Dokic, D.; Latrofa, F.; Mammoli, C.; Lippi, F.; Ceccarelli, C.; Pinchera, A.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 83, No. 1, 1998, p. 40-46.

Research output: Contribution to journalArticle

Chiovato, L. ; Fiore, E. ; Vitti, P. ; Rocchi, R. ; Rago, T. ; Dokic, D. ; Latrofa, F. ; Mammoli, C. ; Lippi, F. ; Ceccarelli, C. ; Pinchera, A. / Outcome of thyroid function in graves' patients treated with radioiodine : Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. In: Journal of Clinical Endocrinology and Metabolism. 1998 ; Vol. 83, No. 1. pp. 40-46.
@article{ea44b7a4e8a14402bb795a89acad3996,
title = "Outcome of thyroid function in graves' patients treated with radioiodine: Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage",
abstract = "We investigated the interrelationship and the influence of thyroid- stimulating antibodies (TSAb), TSH-blocking antibodies (TSHBAb), and of radioiodine (131I)-induced thyroid damage in the early (within 1 yr) outcome of thyroid function in hyperthyroid patients with Graves' disease (GD) treated with 131I. TSAb, TSHBAb, and ultrasound thyroid volume (as an index of thyroid damage) were simultaneously measured before and at 1, 3, 6, and 12 months after 131I in 31 GD patients. One year after radioiodine, 9.7{\%} of patients were hyperthyroid (Hyper-group), requiring methimazole; 12.9{\%} were eu-thyroid (Eu-group); and 77.4{\%} were hypothyroid (Hypo-group). Pretreatment thyroid volume in the Eu-group and Hyper-group was significantly greater (P = 0.009) than in the Hypo-group. Pre-131I TSAb levels were higher in the Hyper-group vs. the Hypo-group (P = 0.01) or the Eu-group (P = 0.03). A significant post-131I increase in TSAb levels occurred in 66{\%} of patients developing hypothyroidism but not in those remaining hyperthyroid. After 131I, TSHBAb appeared in 7 patients, in all but one associated with high levels of TSAb. One year after radioiodine: 1) the mean percent reduction in thyroid volume was greater in the Hypo-group (80.7{\%}) or the Eu- group (83.5{\%}) than in the Hyper-group (35.7{\%}) (P = 0.007 and 0.033, respectively); 2) hypothyroid patients had smaller (P = 0.0058) post-131I thyroids than hyperthyroid patients; and 3) TSAb were still elevated in 75{\%} hypothyroid patients, but all of them had a thyroid volume ≤8 mL, indicating major postradioiodine gland damage. In conclusion: 1) the early outcome of thyroid function after 131I for GD is mainly related to pretreatment thyroid volume and to the degree of its reduction after therapy; 2) high TSAb levels before 131I are associated with a relative resistance to therapy; 3) a postradioiodine increase in TSAb levels is related to the development of hypothyroidism; and 4) the concomitant appearance of TSHBAb and disappearance of TSAb are not frequent after 131I and play a role in the development of early postradioiodine hypothyroidism only in a minority of patients.",
author = "L. Chiovato and E. Fiore and P. Vitti and R. Rocchi and T. Rago and D. Dokic and F. Latrofa and C. Mammoli and F. Lippi and C. Ceccarelli and A. Pinchera",
year = "1998",
doi = "10.1210/jc.83.1.40",
language = "English",
volume = "83",
pages = "40--46",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "1",

}

TY - JOUR

T1 - Outcome of thyroid function in graves' patients treated with radioiodine

T2 - Role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage

AU - Chiovato, L.

AU - Fiore, E.

AU - Vitti, P.

AU - Rocchi, R.

AU - Rago, T.

AU - Dokic, D.

AU - Latrofa, F.

AU - Mammoli, C.

AU - Lippi, F.

AU - Ceccarelli, C.

AU - Pinchera, A.

PY - 1998

Y1 - 1998

N2 - We investigated the interrelationship and the influence of thyroid- stimulating antibodies (TSAb), TSH-blocking antibodies (TSHBAb), and of radioiodine (131I)-induced thyroid damage in the early (within 1 yr) outcome of thyroid function in hyperthyroid patients with Graves' disease (GD) treated with 131I. TSAb, TSHBAb, and ultrasound thyroid volume (as an index of thyroid damage) were simultaneously measured before and at 1, 3, 6, and 12 months after 131I in 31 GD patients. One year after radioiodine, 9.7% of patients were hyperthyroid (Hyper-group), requiring methimazole; 12.9% were eu-thyroid (Eu-group); and 77.4% were hypothyroid (Hypo-group). Pretreatment thyroid volume in the Eu-group and Hyper-group was significantly greater (P = 0.009) than in the Hypo-group. Pre-131I TSAb levels were higher in the Hyper-group vs. the Hypo-group (P = 0.01) or the Eu-group (P = 0.03). A significant post-131I increase in TSAb levels occurred in 66% of patients developing hypothyroidism but not in those remaining hyperthyroid. After 131I, TSHBAb appeared in 7 patients, in all but one associated with high levels of TSAb. One year after radioiodine: 1) the mean percent reduction in thyroid volume was greater in the Hypo-group (80.7%) or the Eu- group (83.5%) than in the Hyper-group (35.7%) (P = 0.007 and 0.033, respectively); 2) hypothyroid patients had smaller (P = 0.0058) post-131I thyroids than hyperthyroid patients; and 3) TSAb were still elevated in 75% hypothyroid patients, but all of them had a thyroid volume ≤8 mL, indicating major postradioiodine gland damage. In conclusion: 1) the early outcome of thyroid function after 131I for GD is mainly related to pretreatment thyroid volume and to the degree of its reduction after therapy; 2) high TSAb levels before 131I are associated with a relative resistance to therapy; 3) a postradioiodine increase in TSAb levels is related to the development of hypothyroidism; and 4) the concomitant appearance of TSHBAb and disappearance of TSAb are not frequent after 131I and play a role in the development of early postradioiodine hypothyroidism only in a minority of patients.

AB - We investigated the interrelationship and the influence of thyroid- stimulating antibodies (TSAb), TSH-blocking antibodies (TSHBAb), and of radioiodine (131I)-induced thyroid damage in the early (within 1 yr) outcome of thyroid function in hyperthyroid patients with Graves' disease (GD) treated with 131I. TSAb, TSHBAb, and ultrasound thyroid volume (as an index of thyroid damage) were simultaneously measured before and at 1, 3, 6, and 12 months after 131I in 31 GD patients. One year after radioiodine, 9.7% of patients were hyperthyroid (Hyper-group), requiring methimazole; 12.9% were eu-thyroid (Eu-group); and 77.4% were hypothyroid (Hypo-group). Pretreatment thyroid volume in the Eu-group and Hyper-group was significantly greater (P = 0.009) than in the Hypo-group. Pre-131I TSAb levels were higher in the Hyper-group vs. the Hypo-group (P = 0.01) or the Eu-group (P = 0.03). A significant post-131I increase in TSAb levels occurred in 66% of patients developing hypothyroidism but not in those remaining hyperthyroid. After 131I, TSHBAb appeared in 7 patients, in all but one associated with high levels of TSAb. One year after radioiodine: 1) the mean percent reduction in thyroid volume was greater in the Hypo-group (80.7%) or the Eu- group (83.5%) than in the Hyper-group (35.7%) (P = 0.007 and 0.033, respectively); 2) hypothyroid patients had smaller (P = 0.0058) post-131I thyroids than hyperthyroid patients; and 3) TSAb were still elevated in 75% hypothyroid patients, but all of them had a thyroid volume ≤8 mL, indicating major postradioiodine gland damage. In conclusion: 1) the early outcome of thyroid function after 131I for GD is mainly related to pretreatment thyroid volume and to the degree of its reduction after therapy; 2) high TSAb levels before 131I are associated with a relative resistance to therapy; 3) a postradioiodine increase in TSAb levels is related to the development of hypothyroidism; and 4) the concomitant appearance of TSHBAb and disappearance of TSAb are not frequent after 131I and play a role in the development of early postradioiodine hypothyroidism only in a minority of patients.

UR - http://www.scopus.com/inward/record.url?scp=14444273438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14444273438&partnerID=8YFLogxK

U2 - 10.1210/jc.83.1.40

DO - 10.1210/jc.83.1.40

M3 - Article

C2 - 9435414

AN - SCOPUS:14444273438

VL - 83

SP - 40

EP - 46

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 1

ER -